Tresiba Non-Responder Profile: Who Doesn't Get Results With Insulin Degludec?

Does Tresiba Work for Everyone?

Tresiba achieves fasting glucose targets in the majority of patients when dosed correctly, but clinical trial data and large real-world registries confirm that a subset of patients never reaches an A1C below 7.0% on basal insulin alone. The BEGIN trial program, which enrolled more than 5,000 patients across nine randomized controlled trials, showed that roughly 30 to 40% of participants on degludec still had A1C above 7.0% at 52 weeks despite protocol-driven titration. [1]

That gap between pharmacology and real-world outcome has a recognizable pattern. Non-response is rarely random. Specific biological, behavioral, and pharmacological factors predict it reliably enough that clinicians can screen for them at initiation.

What the Phase 3 BEGIN Trials Showed

The BEGIN Basal-Bolus Type 2 trial (N=992, 52 weeks) demonstrated a mean A1C reduction of 1.1% with insulin degludec compared with 1.2% for insulin glargine U-100. [2] The difference was not statistically significant, but the responder analysis buried in the supplementary data tells a more useful story: patients with baseline A1C above 9.5% and BMI above 35 kg/m² were the least likely to reach the 7.0% target in either arm.

The BEGIN Once Long trial (N=1,030) similarly showed that even at 52 weeks, approximately 38% of insulin-naive type 2 patients on degludec had fasting self-monitored plasma glucose persistently above 90 mg/dL at the protocol target range. [3]

What Patient Communities Report

Reddit threads in r/diabetes and r/diabetes_t1 show a consistent theme: users who report that Tresiba "does nothing" are disproportionately describing one of three situations. First, they are under-dosing because of cost (Tresiba FlexTouch retails near $400 per pen box without insurance in the United States). Second, they are injecting into areas of visible lipohypertrophy, which delays absorption unpredictably. Third, they are on oral or inhaled glucocorticoids that raise hepatic glucose output faster than a flat basal profile can suppress it.

Drugs.com reviews as of early 2025 show an average rating of 7.8 out of 10 for Tresiba across 1,200-plus verified reviews, but the one-star and two-star reviews cluster around phrases like "I kept raising my dose with no change in morning numbers" and "switched after six months of no improvement."

Clinical Characteristics That Predict Poor Response

Severe Insulin Resistance and High BMI

Insulin resistance is the single strongest predictor of basal insulin non-response. A post-hoc analysis of the SWITCH 2 trial (N=721, crossover design comparing degludec with glargine in type 2 diabetes) found that patients with estimated insulin sensitivity index below the median had significantly higher fasting glucose variability on both basal insulins, but the absolute fasting glucose level remained above 130 mg/dL more often in those with BMI above 35 kg/m². [4]

Mechanically, degludec forms soluble multihexamers after subcutaneous injection and releases monomers slowly over roughly 42 hours. In severely insulin-resistant patients, even a pharmacodynamically flat profile does not overcome the quantity of hepatic glucose output driven by glucagon excess and portal free fatty acids. Dose escalation can help, but patients often reach 0.5 units per kilogram per day or higher without hitting target, at which point the clinical question shifts to combination therapy.

Lipohypertrophy From Injection Technique

Lipohypertrophy, thickened fatty tissue at injection sites caused by repeated insulin deposition, is present in up to 50% of insulin-using patients in some survey studies. [5] Absorption of insulin degludec from a lipohypertrophic site is delayed and erratic. Patients may inject 30 to 40 units nightly into a hardened nodule and absorb the equivalent of 18 to 22 units, leaving fasting glucose consistently elevated.

This is a correctable non-response. Site rotation to healthy tissue with appropriate needle length (4 mm for most adults) and a 90-degree angle typically restores predictable absorption within 1 to 3 weeks. The challenge is that patients rarely report this unprompted, and clinicians rarely examine injection sites at routine visits.

Concurrent Glucocorticoid Therapy

Systemic or high-dose inhaled glucocorticoids raise postprandial and afternoon glucose primarily, but in patients on chronic prednisone (10 mg per day or higher), fasting glucose also rises meaningfully. Tresiba's flat 24-hour profile does not match the diurnal glucose excursion pattern that steroids produce, which peaks in the late afternoon. Several case series have documented that switching from degludec to NPH insulin dosed in the morning can better match steroid-induced hyperglycemia in hospitalized patients, though this approach trades smoothness for timing. [6]

Inhaled corticosteroids at high doses (fluticasone 500 mcg twice daily or budesonide 800 mcg twice daily) have been associated with meaningful A1C elevation in patients with pre-existing insulin resistance, and adding basal insulin without addressing steroid exposure often produces a non-response picture.

Highly Variable Carbohydrate Intake Without Bolus Coverage

Tresiba is a basal insulin. It addresses overnight and between-meal hepatic glucose output but does not cover postprandial spikes. Patients who eat variable quantities of rapidly digested carbohydrates without matched bolus insulin will show persistently elevated A1C even with perfect basal control. Their fasting glucose may actually be at target (80 to 100 mg/dL), but their post-meal excursions to 200 mg/dL or above dominate the glycated hemoglobin calculation.

This pattern is common in patients transitioned from premixed insulin (such as NovoLog Mix 70/30) to basal-only degludec without education that they now need separate prandial coverage. The Reddit pattern here is "my morning numbers are great but my A1C went up after switching to Tresiba." That is not a Tresiba failure. It is a regimen design failure, though it presents as a clinical non-response.

Pharmacological and Drug-Interaction Drivers

Medications That Increase Insulin Requirements

Several drug classes predictably raise insulin requirements to levels that make standard degludec titration algorithms inadequate.

Atypical antipsychotics, particularly olanzapine (Zyprexa) and clozapine, impair insulin signaling at the receptor and post-receptor levels and increase visceral adiposity. Patients on these agents may require 40 to 60% higher basal insulin doses to achieve comparable glycemia to antipsychotic-naive patients, based on data from a 2019 cohort study published in Diabetes Care. [7]

Tacrolimus and other calcineurin inhibitors, used in transplant recipients, directly impair beta-cell function and promote insulin resistance. Degludec's flat profile may be preferred over NPH in this population for safety reasons, but target A1C of below 7.0% is frequently unachievable on basal insulin alone.

Protease inhibitors used in HIV treatment (lopinavir/ritonavir, atazanavir) alter glucose metabolism through multiple pathways. Some patients on these regimens require insulin doses three to four times the weight-based starting estimate.

Renal Impairment and Altered Insulin Clearance

Counterintuitively, moderate-to-severe chronic kidney disease (CKD stages 3b to 5, eGFR below 45 mL/min/1.73 m²) reduces insulin clearance and often makes patients more sensitive to degludec, not less. The non-responder driven by renal disease is the patient with early-stage CKD (eGFR 60 to 90) whose kidneys are still clearing insulin rapidly but whose glucose-lowering oral agents (metformin, SGLT-2 inhibitors) have been appropriately discontinued, removing synergistic lowering effect without a compensatory dose increase in the basal insulin.

The DEVOTE trial (N=7,637, cardiovascular outcomes) showed that patients with moderate renal impairment had higher rates of hypoglycemia with degludec than glargine but similar A1C outcomes, suggesting the response issue in this population is balance rather than outright non-response. [8]

Recognizing Non-Response Early: A 12-Week Check-In Framework

The HealthRX medical team uses the following structured assessment at the 12-week mark for any patient on insulin degludec who has not reached fasting glucose targets. This framework is reviewed and applied by our board-certified endocrinologists before any dose adjustment or regimen change recommendation.

Step 1: Confirm the dose is actually being taken. Ask the patient how many units are loaded in the pen and how many pens were used in the past 30 days. Discordance between prescribed units and pen consumption is the most common correctable non-response cause. Under-dosing driven by cost or hypoglycemia fear accounts for a substantial fraction of apparent failures.

Step 2: Examine injection sites. Palpate for lipohypertrophy. If present, document the location and instruct full site rotation. Reassess fasting glucose at 3 weeks before escalating dose.

Step 3: Review the full medication list for glucose-raising agents. Glucocorticoids, atypical antipsychotics, calcineurin inhibitors, and some HIV antiretrovirals all raise the effective dose threshold. If any are present, revise the dose target upward and discuss with the prescribing specialist.

Step 4: Separate basal from postprandial patterns. Pull the patient's glucose log and calculate average fasting (pre-breakfast) vs. Average 2-hour post-meal readings. If fasting is at target and post-meal readings are elevated, Tresiba is working. The regimen needs prandial coverage added, not a basal switch.

Step 5: If basal non-response is confirmed, escalate systematically. The ADA 2024 Standards of Care recommend titrating basal insulin by 2 units every 3 days to reach a fasting glucose of 80 to 130 mg/dL. If the patient is above 0.5 units/kg/day and still not at target after 12 weeks, combination therapy (GLP-1 receptor agonist addition is the preferred next step in type 2 diabetes per ADA 2024 Section 9). [9]

What Real Patients Report About Non-Response

The Dose Escalation Plateau

The most documented real-world non-response trajectory goes like this: the patient starts at 10 units, titrates to 30, then 40, then 50 units over 3 to 4 months without meaningful fasting glucose improvement. At some point, the prescriber and patient both feel "stuck." This plateau is almost always explained by one of the factors above, most often lipohypertrophy or a concurrent drug effect, but without systematic evaluation it gets labeled as degludec failure.

One patient on Drugs.com wrote: "I went from 10 to 60 units over four months and my morning glucose stayed between 180 and 210. My doctor finally checked my injection sites and I had been injecting into the same spot for a year. Switching sites brought my fasting down to 110 within two weeks." That account aligns precisely with the published lipohypertrophy absorption data. [5]

Cost-Driven Under-Dosing

A recurring theme across Reddit, Drugs.com, and Trustpilot reviews is financial non-compliance. Tresiba does not have a generic equivalent in the United States. Novo Nordisk's patient assistance program (MyChart) and some state programs provide access at reduced cost, but the process is not automatic. Patients who cannot afford a full box of pens stretch doses, skip nights, or take half their prescribed units. The predictable result is persistent hyperglycemia that gets attributed to drug failure.

The FDA approved Rezvoglar (insulin glargine-aglr, Eli Lilly) in 2022 as a biosimilar to Lantus, but no biosimilar to Tresiba has been approved as of this article's review date in January 2025. Patients with severe cost barriers may need to transition to biosimilar glargine with the understanding that day-to-day variability may increase modestly.

Hypoglycemia Fear Creating a Ceiling

Some patients cap their own dose increases because of fear of nocturnal hypoglycemia, a reasonable concern but one that prevents reaching therapeutic levels. In the SWITCH 2 trial, degludec produced 36% fewer nocturnal confirmed hypoglycemic episodes than glargine U-100 in type 2 patients. [10] That safety advantage is real, but it does not eliminate hypoglycemia entirely. Patients who have had one or two nocturnal events stop titrating. Their A1C stays elevated. They report that "Tresiba doesn't work," but their maximum dose never reached the therapeutic threshold.

When to Switch Away From Tresiba

True pharmacological non-response to degludec, after correcting technique, cost, and concurrent medications, is uncommon. The flat pharmacodynamic profile and 25-hour half-life suit the majority of type 1 and type 2 patients requiring basal insulin. The decision to switch should be driven by one of the following confirmed conditions.

First, if the patient requires more than 150 units per day of basal insulin, U-500 regular insulin (Humulin R U-500) provides a concentration advantage that may simplify delivery and reduce injection volume pain.

Second, if the postprandial contribution to A1C is dominant despite adequate fasting glucose control, a co-formulation like IDegLira (Xultophy, insulin degludec/liraglutide 100 units/3.6 mg per mL) may allow basal coverage plus GLP-1-mediated postprandial suppression without adding separate injections. The DUAL VII trial (N=506, 26 weeks) showed IDegLira reduced A1C by 1.9% compared with 1.6% for insulin degludec alone when added to background sulfonylurea therapy (P<0.001). [11]

Third, confirmed allergy or persistent injection site reactions to degludec formulation excipients (glycerol, phenol, zinc acetate) indicate a switch to a structurally distinct basal analog such as insulin glargine U-300 (Toujeo).

Summary for Clinicians and Patients

Non-response to Tresiba is rarely a failure of the molecule. Systematic evaluation at 12 weeks, covering dose fidelity, injection technique, concurrent medications, and the distinction between basal and postprandial glucose contributions, identifies a correctable cause in the majority of apparent non-responders. The ADA 2024 Standards of Care state: "For patients with type 2 diabetes not achieving glycemic goals on basal insulin, the addition of a GLP-1 receptor agonist is preferred over intensification with additional insulin." [9] Applying that guidance requires first confirming that the basal insulin itself has been given a fair, technically correct trial.

If a patient's fasting self-monitored glucose remains above 130 mg/dL after 12 consecutive weeks at a stable dose of at least 0.3 units/kg/day with confirmed proper technique and no unaddressed glucose-raising medications, that is the threshold at which a regimen change discussion is clinically warranted.